Primary Care
Rybelsus Samples for Healthcare Providers
Explore medication sample resources and treatment access support for clinicians prescribing Rybelsus® (semaglutide tablets).
Rybelsus® (semaglutide) is an oral GLP-1 receptor agonist indicated for adults with type 2 diabetes mellitus and for reduction of risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they've had a prior CV event or not (primary and secondary prevention). It is administered as a once-daily tablet and may be prescribed alongside diet and exercise to improve glycemic control. Rybelsus® provides an oral treatment option within the semaglutide product family for appropriate patients.
Built to help reduce friction around treatment access & patient care.
Request Rybelsus® (semaglutide tablets) sample support and treatment access assistance through DocUpdate Concierge.
Request Samples Through DocUpdate
DocUpdate provides free HIPAA-compliant mobile tools that move care forward.
Frequently Asked Questions About Rybelsus Samples
Healthcare providers can download the DocUpdate app and submit a request through Concierge for medication sample and treatment access support.
Rybelsus is an oral semaglutide GLP-1 receptor agonist used in adults with type 2 diabetes.
Rybelsus may be prescribed alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.
DocUpdate is designed for licensed healthcare providers with an active NPI number, including physicians, nurse practitioners, and physician assistants.
No. DocUpdate does not dispense medications or provide direct medication fulfillment. The platform helps healthcare providers navigate medication sample support and treatment access resources through Concierge.
Yes. DocUpdate provides free HIPAA-compliant tools and support resources for healthcare providers.